Skip to main content
Caplight Logo









ImmuneBridge

ImmuneBridge

Private
San Francisco, CaliforniaHealthcare & Life Scienceshttps://immunebridge.com/

Last Round

Seed

Mar 23, 2026

Total Funding Raised

$19.7M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

ImmuneBridge is a biotechnology company developing allogeneic cellular immunotherapies that enhance the body's healing capabilities by expanding cord blood-derived immune stem cells to create a reliable and versatile source for cancer treatments.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

stem cell therapycell-based therapiesregenerative medicineallogeneic cell therapydonor screeningstem cell preservationbiotech platformcell therapy manufacturingdrug discoverymachine learning in biotechoff-the-shelf cell therapysmall moleculecell therapy biotechbiotech R&DGMPgood manufacturing practice

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ImmuneBridge Comparables

Compare ImmuneBridge with similar companies based on industry and business-model similarity.

ImmuneBridge comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
ONK Therapeutics
68%
NK:IO
66%
Garuda Therapeutics
63%

ImmuneBridge Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedMar 23, 2026
SeedApr 10, 2023

ImmuneBridge Investors

Notable investors and investment history

ImmuneBridge investors
InvestorRounds
LongGame VenturesSeed
NFXSeed
One Way VenturesSeed
GaingelsSeed
M VenturesSeed
T.Rx CapitalSeed
Healthspan CapitalSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 29, 2026

    Grew 19% QoQ, from 16 to 19 employees.

  • Mar 24, 2026

    Dr. Rui Tostoes appointed as new CTO.

ImmuneBridge Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

ImmuneBridge Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about ImmuneBridge's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Francisco, California
Employee Range19
Year Founded2018
Last FundingMar 23, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?